| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8453832 | Lung Cancer | 2018 | 19 Pages |
Abstract
The addition of pelareorep to second-line chemotherapy did not improve the PFS of patients with NSCLC. The three-day pelareorep schedule was tolerable. Further research is needed to evaluate the potential benefit in molecular subtypes of NSCLC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Penelope A. Bradbury, Donald G. Morris, Garth Nicholas, Dongsheng Tu, Moustapha Tehfe, John R. Goffin, Frances A. Shepherd, Richard W. Gregg, Jeffrey Rothenstein, Christoper Lee, Sara Kuruvilla, Bruce D. Keith, Vamsee Torri, Normand Blais, Desiree Hao,